Arxxant: Withdrawal of the marketing authorisation application
On 13 March 2007, Eli Lilly Nederland B.V. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for ARXXANT, for the treatment of diabetic retinopathy in adult patients with moderate to severe non-proliferative retinopathy.
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Arxxant (PDF/552.76 KB)Adopted
First published: 18/09/2007
Last updated: 18/09/2007
Eli Lilly withdraws its marketing authorisation application for ARXXANT (PDF/24.99 KB)
First published: 15/03/2007
Last updated: 15/03/2007
Withdrawal letter : Arxxant (PDF/32.7 KB)
First published: 13/03/2007
Last updated: 13/03/2007
Questions and answers on the withdrawal of the marketing application for Arxxant (PDF/51.78 KB)
First published: 22/03/2007
Last updated: 22/03/2007
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').